Cold Chain IQ Editor.
Amid pressure to limit discovery losses and be more ethically responsible, the pharma industry is slowly bowing to the growing weight of evidence to find alternatives to testing on animals.
Astrazeneca and its biologics arm, Medimmune, advance in the R&D race as three new oncology drug candidates see promising developments
Ensuring that temperature-sensitive pharmaceutical products reach their intended destination safely is a primary concern for pharma firms, but it is equally important to consider how they will be stored at the points in the chain.
Ransomware attack could be wake-up call the healthcare sector needs to grasp importance of cyber security and the catastrophic cost of ignoring its threat
Over 60% of you said quality of services was the most important criteria when selecting a CRO. Find out who the TOP 10 CROs are in the industry as voted by our members.
Chanice Henry - Editor of Pharma Logistics IQ gives an update on the temperature controlled logistics industry including investment trends, container usage, packaging design, cost efficiency and planning.
If you were handed with a notice for a clinical trial inspection plan right now, how would you react? - With a feeling of asserted confidence or a rush of slight concern? Wherever you think you would stand on this spectrum, use this infographic to learn from your peers’ mistakes. Pharma IQ invites the expertise of Andy Fisher Senior GCP Inspector... Read more
The transition from paper to electronic Trial Master File (TMF) system, is a significant task, which is further complicated with the varying views and opinions complicating the route to standardisation. This is partially solved by the new directives under construction alongside the EMA’s updated information providing giving insight into inspector’... Read more
The level of process efficiency behind today’s cell and gene therapies is said to rest at a low. The manufacturing behind them is mostly manual, due to the treatments mostly being within early development stages. There are, however, some cases where companies utilise partly automated solutions.
When examining the known future for GMP compliance, there are a range of changes that the industry needs to brace for, including a new EU delegated act focused on investigational medicinal products. Here Pharma IQ outlines the GMP updates the market will soon be facing.